CardiAQ Completes Move of Its Headquarters to a Specialized Facility in Irvine, Calif., and Announces Expansion of Its Product Development Team

Published: Jun 01, 2010

IRVINE, Calif.--(BUSINESS WIRE)--Transcatheter heart valve company CardiAQ Valve Technologies (“CVT”), which is developing the world’s first self-conforming and self-anchoring technology for Transcatheter Mitral Valve Implantation (TMVI), announced today that it has established operations in Irvine, Calif. The 8,500-square-foot operation is a state-of-the-art research, development and manufacturing facility—with microbiology, biochemical, tissue-handling fixation, and tissue-valve-production capabilities. It includes two GMP-certified ‘clean rooms’ for immediate pilot production capability of tissue valves and catheters.

Back to news